Early Experience and Perioperative Risk of GammaTile® for Upfront Brain Metastases: Report from a Prospective Multicenter Study
GT demonstrates a favorable safety profile in upfront brain metastases with a 3.6% rate of serious AEs (grade ≥ 3) within 90 days of the procedure.
Authors
- Sauson Soldozy (ORCID: https://orcid.org/0000-0002-8161-0112)
- Clara Ferreira (ORCID: https://orcid.org/0000-0002-3358-6509)
- Stuart Lee (ORCID: https://orcid.org/0000-0002-5071-7443)
- Rupesh Kotecha (ORCID: https://orcid.org/0000-0001-6927-0402)
- Andrew Sean Venteicher (ORCID: https://orcid.org/0000-0003-0643-0493)
- Sabrina L. Zeller (ORCID: https://orcid.org/0000-0001-7196-9167)
- Kathryn Dusenbery
- Manmeet S. Ahluwalia (ORCID: https://orcid.org/0000-0003-3794-9511)
- Clark C. Chen (ORCID: https://orcid.org/0000-0001-9544-2570)
- Vincent DiNapoli
- Simon Hanft (ORCID: https://orcid.org/0000-0002-9280-8319)
- Matthew Sean Peach (ORCID: https://orcid.org/0000-0002-6877-6919)
- Kimberly Bojanowski-Hoang
- Shaye Busse
Institutions
- Prisma Health (US)
- Baptist Hospital of Miami (US)
- University of Minnesota (US)
- Westchester Medical Center (US)
- Emory University (US)
- Brown University (US)
- Rhode Island Hospital (US)
- Baptist Health South Florida (US)
- Mayfield Brain & Spine (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1093/noajnl/vdae156
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00